<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427310</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP C-02</org_study_id>
    <nct_id>NCT00427310</nct_id>
  </id_info>
  <brief_title>Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery</brief_title>
  <official_title>A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern California Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing. It&#xD;
      is not yet known whether giving fluorouracil into the liver is more effective than no further&#xD;
      treatment for patients with colon cancer undergoing surgery.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying giving infusions of fluorouracil into&#xD;
      the liver in treating patients with Dukes' A, Dukes' B, or Dukes' C colon cancer undergoing&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Determine whether adjuvant therapy with portal hepatic perfusion of&#xD;
      5-fluorouracil and sodium heparin effectively prolongs the disease-free interval and&#xD;
      increases survival in patients undergoing curative resection of adenocarcinoma of the colon.&#xD;
&#xD;
      OUTLINE: Randomized study. Patients are randomized preoperatively; those randomized to Arm 1&#xD;
      begin therapy intraoperatively or within 6 hours of colonic resection. Arm 1: 5-Fluorouracil&#xD;
      plus sodium heparin. Those randomized to Arm 2 receive no adjuvant therapy. Arm 2:&#xD;
      observation (no further treatment).&#xD;
&#xD;
      PROJECTED ACCRUAL: 1,334 patients will be entered over a 4-year period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1984</start_date>
  <completion_date type="Actual">February 2001</completion_date>
  <primary_completion_date type="Actual">September 1989</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free interval</measure>
    <time_frame>From randomization up to 4 years.</time_frame>
    <description>Evidence of treatment failure (presence of tumor in local/regional or distant sites, confirmed by either biopsy or other acceptable evidence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>From randomization up to 4 years.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1158</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Postoperative 5 FU + sodium heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Postoperative observation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>Arm 1: Postoperative 5 FU + sodium heparin</arm_group_label>
    <other_name>5 FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <arm_group_label>Arm 2: Postoperative observation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium heparin</intervention_name>
    <arm_group_label>Arm 1: Postoperative 5 FU + sodium heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  more than one synchronous primary colon tumor&#xD;
&#xD;
          -  white blood cell (WBC) &gt; 4000/cu.mm. and platelet count greater than or equal to&#xD;
             100,000/cu.mm.&#xD;
&#xD;
          -  evidence of adequate renal (serum creatinine less than or equal to 1.5 mg%) and&#xD;
             hepatic function (bilirubin less than or equal to 1.5 mg%; serum glutamic oxaloacetic&#xD;
             transaminase (SGOT) less than or equal to 60 I.U./ml)&#xD;
&#xD;
          -  performance status of 0, 1 or 2&#xD;
&#xD;
          -  Patients with intestinal obstruction are eligible. Preliminary or complementary&#xD;
             colostomy does not preclude entry of a patient provided randomization is carried out&#xD;
             prior to the planned curative resection.&#xD;
&#xD;
          -  The distal margin of the tumor must be greater than or equal to 12 cm from the anal&#xD;
             verge as endoscopically measured with the patient in the knee-chest position.&#xD;
&#xD;
          -  Carcinoembryonic antigen (CEA) must be performed pre-operatively but results need not&#xD;
             be known at the time of randomization.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  malignant colon tumors other than carcinoma, i.e., sarcoma, lymphoma, etc.&#xD;
&#xD;
          -  patients whose tumors demonstrate free perforation&#xD;
&#xD;
          -  previous or concomitant malignancy, regardless of site - except patients with squamous&#xD;
             or basal cell carcinoma of the skin, and carcinoma in situ of the cervix which have&#xD;
             been adequately treated&#xD;
&#xD;
          -  patients who have received prior treatment other than preliminary or complementary&#xD;
             colostomy (radiation, chemotherapy or surgery) for their current malignancy.&#xD;
&#xD;
          -  patients having tumors within 12 cm of the anal verge&#xD;
&#xD;
          -  performance status of 3 or 4&#xD;
&#xD;
          -  patients having non-malignant systemic disease (cardiovascular, renal, hepatic, etc.)&#xD;
             which would preclude their being subject to the chemotherapy treatment option&#xD;
&#xD;
          -  patients who are pregnant at the time of randomization&#xD;
&#xD;
          -  patients with psychiatric or addictive disorders which would preclude obtaining&#xD;
             informed consent&#xD;
&#xD;
          -  patients who have multiple primary tumors involving both the colon and the rectum&#xD;
             which would preclude them from being classified as having only colon cancer or only&#xD;
             rectal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <reference>
    <citation>O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010 Sep 1;28(25):3937-44. doi: 10.1200/JCO.2010.28.9538. Epub 2010 Aug 2.</citation>
    <PMID>20679606</PMID>
  </reference>
  <reference>
    <citation>Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010 Apr;17(4):959-66. doi: 10.1245/s10434-009-0881-y.</citation>
    <PMID>20082144</PMID>
  </reference>
  <reference>
    <citation>Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ; National Cancer Institute. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007 Mar 1;25(7):767-72. Epub 2007 Jan 16.</citation>
    <PMID>17228023</PMID>
  </reference>
  <reference>
    <citation>Kim GP, Colangelo L, Wieand H, et al.: Prognostic and predictive roles of high-degree microsatellite instability (MSI-H) in colon cancer: National Cancer Institute (NCI)-National Surgical Adjuvant Bowel Project (NSABP) collaborative study. [Abstract] American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 27-29 January 2005, Miami, Florida. A-227, 2005.</citation>
  </reference>
  <reference>
    <citation>Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N, Wieand HS. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003 Jan 15;21(2):241-50.</citation>
    <PMID>12525515</PMID>
  </reference>
  <reference>
    <citation>Wolmark N, Colangelo L, Wieand S. National Surgical Adjuvant Breast and Bowel Project trials in colon cancer. Semin Oncol. 2001 Feb;28(1 Suppl 1):9-13.</citation>
    <PMID>11273592</PMID>
  </reference>
  <reference>
    <citation>Dignam JJ, Colangelo L, Tian W, Jones J, Smith R, Wickerham DL, Wolmark N. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999 Nov 17;91(22):1933-40.</citation>
    <PMID>10564677</PMID>
  </reference>
  <reference>
    <citation>Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol. 1999 May;17(5):1349-55.</citation>
    <PMID>10334518</PMID>
  </reference>
  <results_reference>
    <citation>Wolmark N, Rockette H, Petrelli N, et al.: Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02. [Abstract] Proceedings of the American Society of Clinical Oncology 13: A-561, 194, 1994.</citation>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <last_update_submitted>December 31, 2012</last_update_submitted>
  <last_update_submitted_qc>December 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

